| Name | Title | Contact Details |
|---|
Second Sight is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Established in 1933, the American Board of Medical Specialties (ABMS), a not-for-profit organization comprising 24 medical specialty Member Boards, is the pre-eminent entity overseeing the certification of physician specialists in the United States. The primary function of ABMS is to assist its Member Boards in developing and implementing educational and professional standards to evaluate and certify physician specialists. By participating in these initiatives, ABMS also serves as a unique and highly influential voice in the healthcare industry, bringing focus and rigor to issues involving specialization and certification in medicine. ABMS is a designated primary equivalent source of credential information.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Partners Pharmacy is a long-term care pharmacy company in the United States. We offer a full range of services and resources to effectively serve the comprehensive medication needs of residents of skilled nursing facilities, assisted living communities, and alternative care facilities. Our unique AP PassPort™ has dramatically improved medication availability for residents, reduced medication management time for nursing, and improved compliance. Partners Pharmacy currently services over 40,000 beds with services areas in Connecticut, Florida, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Texas, and Virginia. Each location offers unparalleled, personalized service through the combined resources of our local teams and our expanding regional resources. Together we partner with the facilities we service to improve outcomes and reduce costs.
Fairview-University Medical Center is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.